Drug-Drug Interaction Study Between Quinine Sulfate and Rosiglitazone

Completed · Phase 1

Conditions studied: Healthy

In brief

Rosiglitazone is predominantly metabolized by cytochrome P450 (CYP) 2C8. Quinine sulfate is an inhibitor of CYP 2C8. This study will evaluate the effect of multiple doses of quinine sulfate at steady-state on the pharmacokinetics of single-dose rosiglitazone in healthy adult subjects.

Key facts

Study ID
NCT00785213
Run by
Mutual Pharmaceutical Company, Inc.
People needed
23
Starts
2008-09-01
Expected to finish
2008-10-01
Last updated by the study team
2012-08-07

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.